News Release - Eli Lilly and Company
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
All News | Eli Lilly and Company
View All Press Releases. Lilly appoints Thomas J. Fuchs as the company’s first chief AI officer. October 8, 2024. Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials. October 2, 2024.
Lilly.com | Eli Lilly and Company
5 days ago · INDIANAPOLIS , Oct. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Lilly hits record high after Mounjaro fuels forecast raise ...
Aug 8 (Reuters) - Eli Lilly (LLY.N) on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares...
News Release - Eli Lilly and Company
INDIANAPOLIS, May 24, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company's total investment in this site from $3.7 billion to $9 billion.
News Release - Eli Lilly and Company
Aug 16, 2024 · Omvoh™ and its delivery device base are trademarks owned by Eli Lilly and Company. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe.
Lilly.com | Eli Lilly and Company
Sep 12, 2024 · INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI 's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
This is Huge News For Eli Lilly Investors - Yahoo Finance
1 day ago · Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space. The company's path-breaking innovation in using glucagon-like peptide ...
Eli Lilly to trial use of weight loss drugs to combat ...
4 days ago · Eli Lilly to trial use of weight loss drugs to combat unemployment in UK. The U.S. pharmaceutical company and creator of blockbuster obesity injection Zepbound announced Monday that it would ...
FDA approves new Alzheimer's treatment, donanemab from Eli Lilly
Jul 3, 2024 · A new Alzheimer's treatment called donanemab, from drugmaker Eli Lilly, will be marketed under the brand name Kisluna. Eli Lily. The only other Alzheimer's treatment that works in a similar way...